“…The severity of chronic plaque psoriasis is generally assessed according to several tools including the PASI, the body surface area (BSA) and the Physician Global Assessment (PGA) . The multifaceted nature of the psoriasis burden drives the need for a specific focus on health‐related quality of life (HRQoL) and patient‐reported outcome (PRO) measures . Patient's quality of life is commonly assessed by questionnaires including the Dermatology Life Quality Index (DLQI) and the Short Form (SF‐36) Health Survey.…”
Section: Resultsmentioning
confidence: 99%
“…8 The multifaceted nature of the psoriasis burden drives the need for a specific focus on health-related quality of life (HRQoL) and patient-reported outcome (PRO) measures. 9 Patient's quality of life is commonly assessed by questionnaires including the Dermatology Life Quality Index (DLQI) and the Short Form (SF-36) Health Survey. According to the European S3 Guidelines on the systemic treatment of psoriasis vulgaris, moderate-to-severe disease is defined as a PASI score >10.…”
Section: The Concept Of Psoriasis Severitymentioning
Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.
“…The severity of chronic plaque psoriasis is generally assessed according to several tools including the PASI, the body surface area (BSA) and the Physician Global Assessment (PGA) . The multifaceted nature of the psoriasis burden drives the need for a specific focus on health‐related quality of life (HRQoL) and patient‐reported outcome (PRO) measures . Patient's quality of life is commonly assessed by questionnaires including the Dermatology Life Quality Index (DLQI) and the Short Form (SF‐36) Health Survey.…”
Section: Resultsmentioning
confidence: 99%
“…8 The multifaceted nature of the psoriasis burden drives the need for a specific focus on health-related quality of life (HRQoL) and patient-reported outcome (PRO) measures. 9 Patient's quality of life is commonly assessed by questionnaires including the Dermatology Life Quality Index (DLQI) and the Short Form (SF-36) Health Survey. According to the European S3 Guidelines on the systemic treatment of psoriasis vulgaris, moderate-to-severe disease is defined as a PASI score >10.…”
Section: The Concept Of Psoriasis Severitymentioning
Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.
“…The Dermatology Life Quality Index (DLQI) is the most commonly used health‐related quality of life (HRQoL) measure used in patients with psoriasis . It is easy to use, it can detect even small differences in patients’ health status, it is well embedded in dermatological practice and it is endorsed by professional societies . Along with the Psoriasis Area and Severity Index (PASI), it is a recommended end point for efficacy in clinical trials .…”
mentioning
confidence: 99%
“…1,2 It is easy to use, it can detect even small differences in patients' health status, it is well embedded in dermatological practice and it is endorsed by professional societies. 3 Along with the Psoriasis Area and Severity Index (PASI), it is a recommended end point for efficacy in clinical trials. 4 Moreover, it is among the core outcomes collected in large registries of patients with psoriasis worldwide.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
